Medtronic Wraps MiniMed Exchange as Billing Codes and Clinical Data Bolster Device Pipeline

Medtronic fixed the MiniMed exchange ratio at 4.5939, gained CPT codes for Altaviva and Symplicity Spyral, and reported VenaSeal and TITAN 2 data.

Medtronic closed out a busy stretch of corporate engineering and regulatory milestones, capping a week in which the medical technology group finalized the terms of its diabetes spin-off, locked in new U.S. reimbursement codes and rolled out fresh clinical evidence across its surgical and interventional franchises.

The stock finished Friday's session at EUR 79.00, up 1.0 percent, as investors digested the end of the exchange offer tied to the separation of the MiniMed diabetes business.

Exchange ratio set at upper bound

Medtronic had fixed the final exchange ratio for the MiniMed split-off at 4.5939 MiniMed shares for every Medtronic share tendered — the ceiling of the previously announced range. The offer covered a total volume of up to 225,361,295 MiniMed shares, and the deadline for shareholders to tender expired at the end of Friday.

In a filing submitted Thursday, the company refined the arithmetic behind the transaction. Assuming full oversubscription and the exchange of the remaining MiniMed shares, the acceptance volume would come to roughly 55,032,401 Medtronic shares. Without that step, the figure stood at about 49,056,639 Medtronic shares.

The separation is designed to sharpen the group's capital allocation, allowing management to concentrate resources on its surgical and interventional segments while giving the diabetes unit a standalone footing.

Reimbursement wins take shape

Those core segments have been generating their own headlines. On Oct. 1, Medtronic disclosed that the American Medical Association had granted Category I CPT codes for both the Altaviva system and the Symplicity Spyral renal denervation platform. The billing keys take effect in January 2028 and establish a standardized foundation for future reimbursement in the United States — a critical lever for broad payer coverage.

Clinical data and FDA clearance

Clinical momentum has kept pace. At the VEINS 2026 specialist conference on Oct. 3, the company presented results from its global VenaSeal Spectrum study program, which examines use of the system in advanced chronic venous disease. In the 24-month follow-up, 125 treated patients with venous ulcers achieved an 88.1 percent healing rate. Medtronic noted that the procedure is covered by all major U.S. commercial payers.

Separately, exploratory 24-month data from the TITAN 2 study for Altaviva, released Tuesday, showed a sustained reduction in nocturia episodes among treated patients. Ariana L. Smith was named national principal investigator for ENDURANCE, the post-approval follow-up study.

On the surgical side, the FDA on Wednesday granted 510(k) clearance for navigated ApexCut EM blades used in sinus surgery. The instruments link powered surgical tools directly to the company's Stealth AXiS ENT navigation system.

Barclays initiates coverage

Analyst Christopher Pasquale of British investment bank Barclays initiated coverage of Medtronic on Wednesday, assigning the stock an Equal-Weight rating with a price target of $95. The call lands amid a period of visible portfolio restructuring, with the diabetes spin-off and progress on clinical documentation and reimbursement for new technologies drawing close attention from market participants.